Picture of medmix AG logo

MEDX — medmix AG News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Brief: Medmix Says Adjusted EBITDA Margin Guidance for FY 2023 Around 22% (Versus. 23%)

July 20 (Reuters) - medmix AG  MEDX.S :
    * FY 2023 GUIDANCE: 5-7% ORGANIC REVENUE GROWTH (N.C.),
ADJUSTED.
EBITDA MARGIN AROUND 22% (VERSUS. 23%)
    * THROUGHOUT SECOND HALF, PROFITABILITY IS EXPECTED TO
IMPROVE

Source text for Eikon:  ID: 
Further company coverage:  MEDX.S 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on medmix AG

See all news